Fundz

Abbott Laboratories

Campbell, Delaware, United States · Biotechnology, Health Care, Manufacturing

Abbott Laboratories is a global healthcare company that develops and manufactures a wide range of health care products. The company focuses on diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. With a rich history of innovation, Abbott aims to improve lives through its diverse healthcare solutions.

Funding history

  • Debt Financing — $20.0B — Feb 2026

Recent signals

  • Jul 18, 2026: Abbott Laboratories acquires EXAS for growth
  • May 14, 2026: ASL acquires ArightCo for expanded services
  • Apr 16, 2026: SEC 8-K (2.02): On April 16, 2026, Abbott Laboratories reported its financial results for the first quarter of 2026. The announcement included various non-GAAP financial measures, such as net earnings excluding specified items related to acquisitions and stock-based compensation. The results are provided in their news release, which is attached as Exhibit 99.1. This filing indicates strategic financial adjustments which could impact investors and stakeholders, particularly in light of expenses linked to acquisitions and restructuring actions.
  • Mar 09, 2026: SEC 8-K (1.01): On March 9, 2026, Abbott Laboratories entered into a material definitive agreement for the public offering and issuance of senior notes totaling $20,000,000,000 in aggregate principal. This issuance included various tranches: $1,000,000,000 in Floating Rate Notes due 2029, $2,250,000,000 in 3.700% Notes due 2029, $2,500,000,000 in 4.000% Notes due 2031, and $2,750,000,000 in 4.300% Notes due 2033. This significant capital raising effort aims to enhance Abbott's financial position and provide liquidity for corporate purposes, which may include funding ongoing operations and growth initiatives.
  • Feb 28, 2026: Abbott Laboratories to acquire Exact Sciences
  • Feb 26, 2026: Raised $20.0B in Debt Financing
  • Feb 23, 2026: SEC 8-K (1.01): On February 23, 2026, Abbott Laboratories entered into a Pricing Agreement with underwriters including Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc., and J.P. Morgan Securities LLC. As part of this agreement, Abbott will issue and sell $20,000,000,000 in senior notes, which include $1,000,000,000 in Floating Rate Notes due in 2029 and $2,250,000,000 in 3.700% Notes also due in 2029. This financing aims to bolster Abbott's financial position and support its strategic initiatives. The engagement of multiple prominent underwriters signifies strong market confidence in Abbott's upcoming debt issuance.

See plans & pricing → Track Abbott Laboratories’s funding, hiring, and signals — with verified contacts — on Fundz.